Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5277192 | 0.87 | MAOB (0.46) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL22810947 | 0.84 | MAOB (0.41) | MAOB | |
| SCHEMBL5277670 | 0.82 | MAOB (0.45) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL5278588 | 0.81 | — | — | |
| SCHEMBL5275084 | 0.80 | GABRB3 (0.42) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL5280162 | 0.78 | MAOA (0.41) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL5275616 | 0.77 | MAOB (0.56) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL5282810 | 0.76 | MAOA (0.54) | GABRB3GABRA2GABRB2MAOA | |
| SCHEMBL5284348 | 0.76 | MAOB (0.44) | GABRB3GABRA2GABRB2MAOBMAOA | |
| SCHEMBL5274911 | 0.76 | GABRB3 (0.36) | GABRB3GABRA2GABRB2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150359903-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2015-12-17 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359903-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS | ABCB1, CD47, PCNA | GABRB3 861/4885GABRA2 840/4885GABRB2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.